Header graphic for print
Focus on Regulation

Tag Archives: drug marketing

Updates from FDLI’s Advertising & Promotion Conference and the Pharmaceutical & Regulatory Compliance Congress

Recently, industry leaders, members of the FDA bar, and government officials convened at the Food & Drug Law Institute’s (FDLI’s) Advertising & Promotion Conference and the Pharmaceutical & Regulatory Compliance Congress. Topics included policy updates and enforcement priorities from FDA’s centers, Office of Inspector General (OIG) and Department of Justice (DOJ) current and future enforcement

Recent Janssen/J&J Risperdal State Settlement Restricts Certain Promotional Activities for Atypical Antipsychotics

On August 30, 2012, Janssen Pharmaceuticals, Inc. (“Janssen”) and its parent company, Johnson & Johnson, agreed to pay $181 million to 37 states and the District of Columbia to settle allegations that the marketing and advertising of its atypical antipsychotic products (Risperdal, Risperdal Consta, Risperdal M-Tab, and Invega) violated state consumer protection laws.  The settlement imposes